flow trial semaglutide kidney outcomes nejm 2024 hazard ratio Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ ADA 24: FLOW Trial: Kidney

Be patient during dose increases Headaches are most common when your body is adjusting to each new dose

Whether youre exploring your first semaglutide prescription or thinking about switching formats, were here to help you make the choice thats right for you

We monitor all related hormones to keep your balance intact

doi: 10.1136/bmjopen-2018-023458 [DOI] [PMC free article] [PubMed] [Google Scholar] 129.Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U

In July 2024, a retrospective study on overweight or obese adults treated for type 2 diabetes, 81.8% of people receiving tirzepatide (Mounjaro) lost at least 5% of their weight within one year compared to 66.5% of those using semaglutide (Ozempic), a significant difference (which means it did not just happen by chance)